Pediatric Mental Health: Depression and Anxiety

Approximately one in five children and adolescents experience mental health disorders like depression or anxiety. As a primary care clinician, you're often the first line of defense in identifying and managing these conditions. This session will equip you to recognize the signs and symptoms, distinguish them from typical developmental behaviors, and utilize validated screening tools for accurate diagnosis. You'll learn to develop evidence-based treatment plans incorporating both pharmacological and non-pharmacological interventions. We'll also discuss strategies to effectively communicate and collaborate with patients, families, and multidisciplinary teams, addressing challenges like medication adherence, stigma, and care coordination with specialists and schools. Empower yourself to make a significant impact on your young patients' mental health and well-being.

CME/CE Information

1.00 AMA PRA Category 1 Credits™ or 0.90 AANP, including 0.36 AANP Pharm

Release Date: 5/7/2026

Expiration Date: 6/28/2026

Topics

Faculty

Ajay Shah, MD

Learning Objectives

Identify the signs and symptoms of depression and anxiety in children and adolescents
Utilize validated screening tools and assessment techniques to accurately diagnose depression and anxiety disorders in pediatric patients
Develop evidence-based treatment plans that incorporate pharmacological and non-pharmacological interventions appropriate for each condition
Facilitate effective communication and collaboration with patients, families, and multidisciplinary teams, surrounding a child's mental health management
Address common challenges in pediatric mental health care, such as medication adherence, stigma, and coordinating care with mental health specialists and teachers

Faculty

Ajay Shah, MD

Assistant Professor, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas

Medical Director, Outpatient Child and Adolescent Psychiatry, Texas Children's Hospital, Houston, Texas

Learn More

Disclosures

All individuals in control of content for this activity (including faculty, moderator, editors, reviewers) have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners^® (AANP) through the joint providership of Pri-Med Institute and Baylor College of Medicine. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 0.90 contact hours, which includes 0.36 hours of pharmacology.

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.